new research for schizophrenia

• Skip to main content
• Keyboard shortcuts for audio player

• Your Health
• Treatments & Tests
• Health Inc.
• Public Health

Shots - Health News

A new kind of drug for schizophrenia promises fewer side effects.

Sydney Lupkin

For the first time in decades, the FDA has approved a new type of schizophrenia drug

The Food and Drug Administration approved Cobenfy, a twice-a-day medication that is a new kind of treatment for schizophrenia in adults. Steve Belkowitz/Bristol Myers Squibb hide caption

For the first time in decades, the Food and Drug Administration has approved a new type of drug for schizophrenia.

The twice-a-day pill to be marketed by Bristol Myers Squibb will be called Cobenfy , though it had been referred to as KarXT during development. Its main advantage is that it appears to have fewer side effects than current medicines.

It keeps people with schizophrenia in school and on the job. Why won't insurance pay?

That difference has captured the attention of patients like Tiffany, a librarian in Oklahoma. She asked us to use only her first name because of the stigma associated with schizophrenia.

When she was first put on an antipsychotic drug, she says it made her feel like a zombie. Watching a video of her birthday party that year, she didn’t recognize herself.

“I was opening presents — everyone was happy. And I'm just sitting there like, there's nothing going on. Like, I'm staring at a blank wall,” she says. “And so I lied and I told everyone I was better.”

So she stopped taking the drug and basically white-knuckled it for years until she experienced another psychotic episode.

Then, she played what she calls the “meds game,” trying different pills until one worked for her. But some of the side effects were brutal. Common antipsychotic drugs can cause weight gain and increase the risk for diabetes.

One gave Tiffany a movement disorder.

“So I was pacing in my office for eight hours a day, and it is exactly 3 1/2 steps, turn, 3 1/2 steps, turn,” she says. “It was a nightmare.”

Decades of dopamine-focused drugs

Since the first antipsychotic drug was introduced in the 1950s, the subsequent medications to treat psychosis act on the same chemical that helps the brain communicate with the rest of the body: dopamine.

“The dopamine hypothesis proposed that schizophrenia is associated with excessive dopamine neurotransmission — so too much dopamine activity,” says Dr. Ann Shinn , a psychiatrist who directs clinical research on schizophrenia and bipolar disorder at McLean Hospital near Boston.

Dopamine is the neurotransmitter usually associated with reward and learning, but it actually has a lot of functions. It also plays a role in controlling movement, for example — that’s why that one drug made Tiffany pace.

The new drug targets different brain receptors

Cobenfy is the first new medicine for psychosis that does not act on dopamine.

“I became really interested in schizophrenia and through that work became really interested in the idea of targeting muscarinic receptors because here was a serendipitous clinical finding that suggested potential efficacy, which is really hard to come by in psychiatry,” says the drug’s lead inventor, Andrew Miller .

He’s talking about a 1997 study in Alzheimer’s patients of a drug that was shelved even though it reduced psychosis.

The muscarinic receptors got their name because they respond to muscarine, a chemical in some mushrooms. The problem for developing a drug to activate them in the brain is that they can trigger receptors in the gastrointestinal tract. Patients couldn’t tolerate it.

So Miller and his team decided to add a second medicine — one already used for overactive bladder — to shut down the gastrointestinal receptors. The trick: That medication can’t cross into the brain from the blood.

That means it shuts down the muscarinic receptors in the body but doesn’t stop the first drug from doing its job in the brain.

“Basically Karuna kind of did this brilliant thing of putting it all together in a combination drug,” Shinn says.

She’s talking about Miller’s company, Karuna Therapeutics, which was acquired by pharmaceutical heavyweight Bristol Myers Squib b for $14 billion dollars earlier this year.

How much it will cost?

Bristol Myers Squibb says the drug will be available starting in October at $1,850 a month, which is in line with other schizophrenia treatments. It’s unclear how easy it will be for patients to get insurance coverage for Cobenfy.

“If it's like a lot of the other new medications, insurance is generally going to mandate that people try at least two generic medicines first … before they will pay for it,” says Dr. Jacob Ballon , an associate professor of psychiatry at Stanford University.

Still, he has a lot of patients — and their parents — who are excited about a potential new treatment option, he says. Ballon is working on an ongoing study of how Cobenfy fits in with existing drugs and whether they can be used together.

While the new medicine isn’t for everyone, it could help patients who’ve had trouble with existing treatments.

The FDA based its approval on 5-week double-blind, placebo-controlled studies. That means some patients received Cobenfy and others got a placebo, but neither the patients nor the clinicians knew which was which until the study was over. The short study length has prompted some experts to point out that questions remain about the drug’s long-term safety and efficacy .

Common side effects with Cobenfy include nausea, constipation and rapid heartbeat.

As for Tiffany, she’s interested in trying the drug down the road. Unlike previous drugs which only tackled the so-called positive symptoms of schizophrenia, like hallucinations and delusions, Cobenfy has been shown to decrease the “negative” symptoms, such as apathy and lack of motivation.

“Every time I have an episode, I lose bits of myself and bits of functionality … and that's not fair to my husband, and I hate it,” she says. “So if I could have something that would help me have a little bit more initiative, that would be wonderful.”

She also has some advice for people with schizophrenia who are still searching for the right treatment.

“Just keep trying,” she says. “It's really hard to go on and off medications, but when you find the right one, it makes a huge difference — night and day.”

• schizophrenia
• mental health
• Pharmaceuticals

Transforming the understanding and treatment of mental illnesses.

Información en español

• Science News
• Meetings and Events
• Social Media
• Press Resources
• Email Updates
• Innovation Speaker Series

Science News About Schizophrenia

December 16, 2024 • Research Highlight

An NIMH-funded study identified consistent links between brain connectivity and cognitive function in people with early stage psychosis and people at high risk who later developed psychosis.

May 23, 2024 • Press Release

An NIMH-funded research consortium has produced the largest and most advanced multidimensional maps of gene regulation networks in the brains of people with and without mental disorders.

March 25, 2024 • Research Highlight

Research funded by NIMH found a link between a low level of social interest among people with psychotic disorders and brain regions in the social motivation system.

September 25, 2023 • Feature Story • 75th Anniversary

The Recovery After an Initial Schizophrenia Episode research initiative, launched by NIMH to test the effectiveness of coordinated specialty care to treat first-episode psychosis, has transformed the mental health landscape in the United States and helped thousands of people with schizophrenia achieve better outcomes.

November 29, 2022 • Research Highlight

In a comprehensive postmortem genetic analysis of the caudate nucleus in the brain, NIMH-supported researchers identified many genes associated with schizophrenia risk, including a gene that regulates the flow of the chemical messenger dopamine.

August 16, 2022 • Research Highlight

Researchers used computational methods to automatically detect abnormalities in spoken language that could be used to predict symptoms of psychotic disorders including schizophrenia.

March 8, 2022 • Press Release

A new study shows the use of a clinical decision support system to prompt the use of shared decision-making tools, such as handouts, may result in positive impacts on long-term cardiovascular health in patients with serious mental illness.

February 9, 2021 • Press Release

A new study conducted by researchers at NIMH suggests that differences in the expression of gene transcripts – readouts copied from DNA that help maintain and build our cells – may hold the key to understanding how mental disorders with shared genetic risk factors result in different patterns of onset, symptoms, course of illness, and treatment responses.

February 2, 2021 • Research Highlight

The Early Psychosis Intervention Network (EPINET), an NIMH initiative aimed at determining how to best provide treatment for individuals experiencing symptoms of early psychosis, is increasing access to resources for researchers, providers, and families through a growing network of research hubs and a new website.

September 15, 2020 • Research Highlight

NIMH has joined with other NIH Institutes in launching an new Accelerating Medicines Partnership focused on advancing the development of better ways to identify and treat those at clinical high risk for psychosis.

October 24, 2019 • Press Release

Mice with an impaired version of one the few genes definitively linked to schizophrenia showed abnormalities in working memory, mimicking those commonly seen in schizophrenia patients.

September 23, 2019 • Press Release

Gene expression regulators work together to raise an individual’s risk of developing schizophrenia. Schizophrenia-like gene expression changes modeled in human neurons matched changes found in patients’ brains.

September 20, 2019 • Press Release

NIMH awarded six research grants for studies to develop a learning health care system for the treatment of early psychosis.

September 3, 2019 • Institute Update

Mental health research center directors emerged from a recent meeting with a renewed commitment to help each other achieve their common mission – to transform care of children, adolescents and adults with severe psychiatric disorders.

February 20, 2019 • Press Release

Researchers have shown that a type of magnetic resonance imaging — called neuromelanin-sensitive MRI (NM-MRI) — is a potential biomarker for psychosis. NM-MRI signal was found to be a marker of dopamine function in people with schizophrenia and an indicator of the severity of psychotic symptoms in people with this mental illness.

January 17, 2019 • Press Release

A new study in rodents has demonstrated, for the first time, that the brain’s cerebellum plays a role in controlling reward and social preference behavior—findings that shed light on the brain circuits critical to the affective and social dysfunction seen across multiple psychiatric disorders.

December 20, 2018 • Press Release

PsychENCODE researchers are discovering the biological mechanisms by which mental illness risk genes work in the human brain.

December 11, 2018 • Science Update

Two recent studies add to the evidence that team-based early intervention services are feasible in real-world health care settings and result in improved outcomes for patients.

December 4, 2018 • Science Update

NIMH-funded scientists have discovered a pattern in the way a brain circuit works that may help predict the onset of psychosis. High levels of chatter, or “hyperconnectivity,” in a circuit involving the cerebellum, thalamus, and cortex emerged as a potential “neural signature” in a functional magnetic resonance imaging (fMRI) study.

July 24, 2018 • Science Update

High levels of maternal inflammation during pregnancy have been linked to effects in children, including reduced brain circuit communications and altered long-distance brain wiring at birth, poorer cognitive function at one year – and to reduced impulse control and working memory at two years.

March 1, 2018 • Science Update

Depression, schizophrenia and autism spectrum disorder share some of the same patterns of suspect gene expression – molecular signatures.

January 29, 2018 • Press Release

Scientists have deciphered the molecular structure of a widely-prescribed antipsychotic docked in its key human brain receptor. The discovery may hold clues to designing better treatments for schizophrenia, bipolar disorder and other mental illnesses.

August 18, 2017 • Press Release

Star-shaped support brain cells, astrocytes, growing in 3-D “organoids” in a dish develop similarly as those in human brain tissue.

August 7, 2017 • Science Update

Support cells generated from patients with childhood onset schizophrenia stunted neural circuit development when grafted into developing mouse brains.

July 24, 2017 • Science Update

Researchers have produced the first direct evidence that parts of our brains implicated in mental disorders may be shaped by a “residual echo” from our ancient past. The more a person’s genome carries genetic vestiges of Neanderthals, the more certain parts of his or her brain and skull resemble those of humans’ evolutionary cousins that went extinct 40,000 years ago.

May 3, 2017 • Press Release

Long overlooked as a mere “relay,” an egg-like structure in the middle of the brain also turns out to play a pivotal role in tuning-up thinking circuity. A trio of studies in mice are revealing that the thalamus sustains the ability to distinguish categories and hold thoughts in mind. It might even become a target for interventions for psychiatric disorders marked by working memory problems, such as schizophrenia.

April 19, 2017 • Science Update

Brain scans reveal that fluctuations in estrogen can trigger atypical functioning in a key brain memory circuit in women with a common version of a gene. Since working memory function is often disturbed in mental disorders, such gene-hormone interactions are suspect mechanisms that may confer risk.

April 6, 2017 • Press Release

A new study shows that young people with first episode psychosis have a much higher death rate than previously thought. Researchers looked at people aged 16-30 and found that the group died at a rate at least 24 times greater than the same age group in the general population.

September 27, 2016 • Science Update

Scientists have pinpointed several schizophrenia-related gene variants that alter expression of other genes in illness-implicated circuitry of the human brain.

August 12, 2016 • Science Update

Schizophrenia, autism risk gene trajectories point to shared causes

March 11, 2016 • Press Release

Scientists have discovered secrets of how the brain recalls experiences of being in a particular location in making informed choices.

February 1, 2016 • Press Release

Coordinated Specialty Care for First Episode Psychosis is Cost Effective

January 27, 2016 • Press Release

Versions of a gene linked to schizophrenia may trigger runaway pruning of the teenage brain’s still-maturing communications infrastructure.The gene switched on more in people with the suspect versions, who faced a higher risk of developing the disorder.

December 8, 2015 • Press Release

Three biomarker-based categories, called “biotypes,” outperformed traditional diagnoses, such as schizophrenia and bipolar disorder with psychosis, in sorting psychosis cases into distinct subgroups on the basis of brain biology

November 4, 2015 • Science Update

Recent articles in JAMA Psychiatry report and comment on the premature mortality seen among adults with schizophrenia; NIMH research is underway to reduce health risk factors in people with serious mental illness.

October 20, 2015 • Press Release

New research shows that a team-based, coordinated specialty care treatment plan produces better outcomes than typical community care for people with first episode psychosis. Investigators also found that treatment is most effective for people who receive care soon after psychotic symptoms begin.

April 17, 2015 • Live Chat

NIMH Google+ Hangout on First-Episode Psychosis

January 29, 2015 • Science Update

Risk genes for different mental disorders work through same pathways

December 12, 2014 • Press Release

Many patients with first-episode psychosis receive medications that do not meet guidelines. A study finds that almost 40 % of people with first-episode psychosis in community mental health clinics across the country might benefit from medication treatment changes.

October 8, 2014 • Press Release

Many patients with psychosis develop health risks associated with premature death early in the course of their mental illness, researchers have found.

August 18, 2014 • Press Release

Researchers have shown in patients’ cells how a rare mutation in a suspect gene disrupts the expression of dozens of other genes underlying neural connections.

July 22, 2014 • Press Release

The largest genomic dragnet of any psychiatric disorder to date has unmasked 108 chromosomal sites harboring inherited variations in the genetic code linked to schizophrenia, 83 of which had not been previously reported.

May 23, 2014 • Science Update

Treatment adherence is a problem among people with schizophrenia, who may not take medications because they don’t perceive its need or benefit, don’t like the side effects, or forget. To combat this issue, long-acting injectable medications are administered every 2-4 weeks. But are the new forms of these drugs better than the old ones?

April 23, 2014 • Science Update

NIMH’s Dr. Robert Heinssen Receives Special Presidential Commendation from APA

March 13, 2014 • Science Update

The hippocampus houses learning and memory—specifically the storage of knowledge of who, what, where, and when. Using a special transgenic mouse, researchers have now pinpointed a hippocampal region called CA2 that is important for social memory, the ability of animal to recognize another of the same species. Understanding this region could be useful in understanding and treating disorders characterized by altered social behaviors such as schizophrenia, bipolar disorder, and autism.

Potential schizophrenia treatment, discovered at Vanderbilt and being developed by Neumora Therapeutics, entering Phase 1 clinical trial 

Media Inquiries

• 615-322-6397 Email

Latest Stories

• Important commuting, transportation and parking reminders
• Vanderbilt Peabody College announces scholarship for Nashville area educators
• Tony Stewart, Gertrude Conaway Vanderbilt Chair in the Humanities, emeritus, has died

Share this Story

Dec 4, 2023, 12:49 PM

A potential schizophrenia treatment discovered through the Warren Center for Neuroscience Drug Discovery has been cleared by the U.S. Food and Drug Administration for use in phase 1 clinical trials—the third WCNDD therapeutic to reach that benchmark.  

“Vanderbilt is proud that a discovery by our researchers at the Warren Center is now a significant step closer to helping improve the lives of people with schizophrenia,” Chancellor Daniel Diermeier said. “Our work with Neumora is the very definition of translational research and the work we aim to do every day, which is applying innovation and discovery to help address the world’s most complex challenges.”   

The clinical trial has been initiated by Neumora Therapeutics Inc. , a clinical-stage biopharmaceutical company founded to confront the global brain disease crisis by taking a fundamentally different approach to the way treatments are developed. Vanderbilt and Neumora signed an exclusive, worldwide license and a research collaboration agreement for two novel series of M4 receptor modulator compounds, including NMRA-266, in February 2022.  

Vanderbilt’s agreement with Neumora was centered around the M 4 muscarinic receptor, which NMRA-266 targets through positive allosteric modulation. In preclinical studies conducted by Conn and Lindsley, NMRA-266 was found to be highly selective to the M 4 receptor, the area of the brain that regulates neurotransmission of dopamine. Overactive transmission of dopamine is connected to the positive, negative and cognitive symptoms of schizophrenia.   

“The M 4 PAM story has been a Homer-style Odyssey to get to this point and represents almost 20 years of research funded by National Institutes of Health, the William K. Warren Foundation and pharmaceutical companies,” said Lindsley, also a University Professor of pharmacology, biochemistry and chemistry who holds the William K. Warren, Jr. Chair in Medicine. “This mechanism and NMRA-266 represent a potential game-changer for schizophrenic patients and their families. Moreover, this success is a testament to the virtue of academic drug discovery and Vanderbilt’s commitment to supporting the WCNDD, a clinical-stage biotech enterprise within the university.”  

For the WCNDD to have such regular production of clinical assets when up against diverse neuroscience pipeline is unprecedented among academic drug discovery centers, according to Lindsley.  

“NMRA-266 entering phase 1 trials highlights the complementary relationship between university researchers and industry partners,” said Vice Provost for Research and Innovation Padma Raghavan. “By pairing our faculty’s ingenuity with the private sector’s commercialization know-how, we are able to bring life-changing discoveries to patients in need faster.”  

Schizophrenia spectrum disorders affect 3.7 million U.S. adults, a figure up to three times higher than previously understood, according to a recent study . This fundamentally different mechanism that NMRA-266 acts through is very selective for brain circuits involved in schizophrenia, which means in is unlikely to have the adverse effects of current dopamine antagonists—resulting in an improved standard of care for people with schizophrenia.  

“The initiation of this phase 1 study is an important step in the development of NMRA-266. In pre-clinical studies NMRA-266 demonstrated a favorable pharmacologic profile that includes high potency and selectivity for the M 4  receptor subtype, meriting its advancement into the clinic,” Dr. Robert Lenz, executive vice president and head of research and development at Neumora, said in a  release . “With its pre-clinical profile and clinical validation of the M 4  muscarinic receptor class in treating schizophrenia, we believe that NMRA-266 has strong potential as a treatment for neuropsychiatric disorders.”  

Human clinical trials are a significant advancement in a five-step  drug development process . Drug discovery research begins in the lab and is followed by preclinical research to answer basic questions about safety. Then there is clinical research to ensure that the treatment is safe and effective. The FDA then reviews all submitted data. If approved, the therapeutic will be made available for use by the public and be monitored for safety by the FDA for as long as it is available.  

The Vanderbilt-Neumora collaboration was facilitated by the   Center for Technology Transfer and Commercialization . Vanderbilt researchers who contributed to research around NMRA-266 and the power of academic drug discovery include Darren W. Engers , Aaron Bender ,  Olivier Boutaud ,  Thomas Bridges , Julie Engers ,  Alison Gregro , Carrie Jones ,  Colleen Niswender ,  Jerri Rook and Kayla Temple .  

Explore Story Topics

• Aaron Bender
• Allison Gregro
• Basic Sciences
• biomedical research
• Carrie Jones
• clinical trial
• Colleen Niswender
• Craig Lindsley
• Darren Engers
• Discovery Vanderbilt
• featured myvu
• featured research
• Food and Drug Administration
• Jeffrey Conn
• Julie Engers
• Kayla Temple
• MyVU latest headlines
• neuroscience
• Olivier Boutaud
• pharmacology
• schizophrenia
• School of Medicine Basic Sciences
• Thomas Bridges
• Warren Center for Neuroscience Drug Discovery

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

• View all journals

Schizophrenia articles from across Nature Portfolio

Schizophrenia is a severe and debilitating psychiatric disorder that involves psychotic symptoms such as hallucinations and delusions, accompanied with regressive behaviour.

Latest Research and Reviews

Efficacy and acceptability of pharmacological interventions for tardive dyskinesia in people with schizophrenia or mood disorders: a systematic review and network meta-analysis

• Marco Solmi
• Michele Fornaro
• Christoph U. Correll

Heterogeneous patterns of brain atrophy in schizophrenia localize to a common brain network

Utilizing heterogeneous results from the published studies on brain atrophy in schizophrenia, the authors identify a common brain network for schizophrenia that is stable with disease progression and across different clusters of schizophrenia symptoms.

• Ahmed T. Makhlouf
• William Drew
• Shan H. Siddiqi

Adolescent maturation of dorsolateral prefrontal cortex glutamate:GABA and cognitive function is supported by dopamine-related neurobiology

• Ashley C. Parr
• Maria I. Perica
• Beatriz Luna

Glial cell deficits are a key feature of schizophrenia: implications for neuronal circuit maintenance and histological differentiation from classical neurodegeneration

• Hans-Gert Bernstein
• Madeleine Nussbaumer
• Johann Steiner

Synaptotagmin-11 deficiency mediates schizophrenia-like behaviors in mice via dopamine over-transmission

Schizophrenia is a severe psychiatric disorder and the pathogenesis remains unclear. Here, the authors show a potential role for synaptotagmin-11 in schizophrenia-related behavior through dopamine over-transmission.

• Changhe Wang

Impacts of CACNB4 overexpression on dendritic spine density in both sexes and relevance to schizophrenia

• Emily M. Parker
• Nathan L. Kindja
• Robert A. Sweet

News and Comment

New schizophrenia drug could treat Alzheimer’s disease

Half a dozen drugs are in trials for conditions of the brain, but success is not guaranteed.

The dopaminergic basis of negative symptoms in schizophrenia: an addendum

• Ana Weidenauer
• Irena Dajic
• Matthäus Willeit

Pre-stimulus neural activity and visual perception in schizophrenia

• Troby Ka-Yan Lui

Revolutionary drug for schizophrenia wins US approval

The medication is the first in decades to have a different mode of action from those of current drugs, achieving better symptom relief with fewer side effects.

• Elie Dolgin

Messiah or pariah? Psychosis, science, and finding meaning in lived experience

Diagnosed with adult-onset schizophrenia shortly after his 24th birthday, the author transitioned from a perceived state of spiritual awakening to grappling with one of the most stigmatized illnesses. Initially, he internalized societal stereotypes, envisioning a future as a marginalized individual. However, with support from family and providers, he re-engaged with school and work, fostering an expectation of normalcy despite early struggles. The author discusses his psychotic episodes, marked by rapture, absurdity, and terror, in light of current neurobiological literature and mechanistic hypotheses such as salience network dysfunction and impaired corollary discharge. Over time, he sought to reconcile these intense memories with scientific understanding to find meaning in his lived experience. As co-chair of the Accelerating Medicines Partnership® Schizophrenia (AMP® SCZ), he advocates for an integrative approach combining scientific inquiry and lived experience. This perspective not only fosters a more accurate comprehension of psychosis but may also enhance research and care.

• Carlos A. Larrauri

Put people at the heart of schizophrenia research

Scientists, health-care professionals, carers and individuals affected by the condition must work more closely with one another to improve people’s lives.

• Constanza Morén

Quick links

• Explore articles by subject
• Guide to authors
• Editorial policies

Media Center

• Events & Webinars
• Healthy Minds TV
• Email Signup
• Get Involved
• Anxiety Disorders
• Attention-Deficit Hyperactivity Disorder (ADHD)
• Autism Spectrum Disorder (ASD)
• Bipolar Disorder
• Borderline Personality Disorder (BPD)
• Eating Disorders
• Mental Illness (General)
• Obsessive-Compulsive Disorder (OCD)
• Inaccessible
• Post-Traumatic Stress Disorder (PTSD)

Schizophrenia

• Suicide Prevention
• Other Brain-Related Illnesses
• Basic Research
• New Technologies
• Early Intervention/ Diagnostic Tools
• Next Generation Therapies
• Donate Today
• Make a Memorial/Tribute Gift
• Create an Event/Memorial Page
• Find an Event/Memorial Page
• Make a Stock/Securities Gift/IRA Charitable Rollover Gift
• Donate Cryptocurrency
• Other Giving Opportunities
• Monthly Giving
• Planned Giving
• Research Partners
• Donor Advised Funds
• Workplace Giving
• Team Up for Research!
• Sponsorship Opportunities

$178M Awarded to Schizophrenia Research since 1987

The Latest Research Discoveries

Posted: September 12, 2024

Variations in Schizophrenia-Linked Gene Are Linked With Pathology in Prefrontal Cortex, Impairing Cognition

Posted: February 01, 2024

In Young Psychosis Patients, Study Reveals Changes Over Time in Brain Molecules Called Metabolites

Posted: January 18, 2024

New, Potential First-in-Class Schizophrenia Medicine Reduced Positive and Negative Symptoms in Phase 3 Trial

Posted: January 11, 2024

In Trial, Magnetic Seizure Therapy (MST) Was Just as Effective as Electroconvulsive Therapy (ECT) in Treating Severe Depression, and Likely Safer

Posted: November 28, 2023

A Connectivity Signature Predicting Response to Antipsychotic Therapy is Identified in First-Episode Psychosis Patients

Posted: November 09, 2023

Anti-Inflammatory Medicine Reduced Positive Symptom Severity in Chronic Schizophrenia Patients with Elevated Inflammatory Markers

Posted: October 16, 2023

A Problem With Energy-Producing Mitochondria May Increase Risk for Schizophrenia

Posted: September 21, 2023

Combined Psychosocial Treatment Helped Schizophrenia Patients with Motivational Negative Symptoms

Posted: September 05, 2023

In Schizophrenia, Reducing the Impact of Medications on One Neurotransmitter System Could Yield Gains in Cognition

Posted: July 24, 2023

Two Forms of Non-Drug Therapy Helped Reduce Impulsive Aggression in Schizophrenia

Posted: May 30, 2023

In Young Men, 15% of Schizophrenia Might Be Prevented If Cannabis Use Disorder Is Not Present, Study Finds

Posted: May 16, 2023

Research Suggests How Working Memory Retains, Manipulates, and Deletes Specific Items

Posted: March 29, 2023

Study Suggests Why Cannabidiol (CBD) Can Help To Reduce Epileptic Seizures in Severe Cases

Posted: February 23, 2023

Study of How Schizophrenia Symptoms Affect One Another Finds Anhedonia and Low Motivation to Be Plausible Targets of Focused Treatments

Posted: January 19, 2023

Genetic Data Suggest How Immune Abnormalities May Help Cause Psychiatric Illness, Across Multiple Disorders

Posted: December 14, 2022

Sensory and Motor-System Abnormalities May Help Identify High-Risk Individuals Who Will Develop Psychosis

Study Reveals How Gene Regulation Helps Determine Brain Development, Shedding Light on Neurodevelopmental Disorders

Posted: December 13, 2022

In Hippocampus, Protein's Malfunction Is Potential Link to Memory and Other Impairments Seen in Schizophrenia

Comprehensive Analysis Suggests Metacognitive Training Can Be Effective in Schizophrenia and Psychotic Disorders

Maternal Sleep Apnea in Pregnancy Is Linked in Animal Model With Autism-like Behavioral Impacts in Offspring

Stem Cell Technology Helps Identify a Potential Causal Mechanism in Schizophrenia That Could Be Targeted

Difficulty Updating Prior Knowledge With New Perceptions Is Linked by Researchers With Psychosis Symptoms

Precise Imaging Reveals How a Key Receptor's Signaling Is Modulated—A Spur to Improving Psychiatric and Other Drugs

Posted: December 12, 2022

Lab-Grown Human Neurons Transplanted into the Rat Brain Grew, Connected, and Promise to Shed Light on Psychiatric Illness

Posted: December 01, 2022

Important New Research on Schizophrenia Genetics Provides Strongest Evidence to Date of Problems at the Brain’s Synapses

Posted: September 30, 2021

Researchers Propose a New Understanding of Dopamine's Role in Learning and Memory

Posted: August 12, 2021

Obesity Is a Risk Factor for Brain-Structure Changes in Schizophrenia and Bipolar Disorder, 2 Studies Show

Posted: July 08, 2021

Negative Symptoms in Schizophrenia Worsened Under Pandemic Conditions, Study Finds

Posted: July 01, 2021

Study Links Schizophrenia Medicines’ Anticholinergic Impact to Risk of Cognitive Impairment

Posted: June 21, 2021

Experiments Reveal How a Circuit 'Resets' When the Brain Learns to Respond to New Conditions

Posted: May 27, 2021

Testing a Computer-Generated Model to Predict High-Risk Youths' Transition to Psychosis

Posted: May 05, 2021

Using Brainwave Patterns to Predict and Understand Psychiatric Disorders

Posted: March 25, 2021

In Early Schizophrenia, Long-Acting Injectable Antipsychotic Treatment Lengthened Time to First Hospitalization

Posted: March 18, 2021

Hyperactivity in Two Wide-Ranging Neural Networks is Discovered in Schizophrenia Patients

Posted: February 18, 2021

In Schizophrenia, Differences in the Brain’s Energy Pathways Suggest Possible New Treatment Target

Posted: February 04, 2021

People With Schizophrenia Have Increased Risk of Dying From COVID-19, Research Reveals

Posted: January 28, 2021

Combining the Antipsychotic Olanzapine with an Opioid-Receptor Blocker Significantly Limited Weight-Gain Risk in Schizophrenia Patients

Posted: November 12, 2020

Study Reveals Adults With Mental Disorders Are At Significantly Higher Risk of COVID-19 and Have Poorer Outcomes

Posted: October 29, 2020

Researchers Discover a Role for Immune Cells Called Microglia in Inhibiting Brain Activity and Regulating Behavior

Posted: October 22, 2020

Drugs Targeting the Glutamate System Warrant Continued Development for Schizophrenia, Study Finds

Posted: October 08, 2020

New Study Demonstrates Non-Invasive tDCS Brain Stimulation Can Enhance Cognitive Control in Schizophrenia Patients

Posted: October 01, 2020

Study Makes Case for Rigorous Re-Testing of Opioid Antagonists to Treat Schizophrenia

Posted: September 17, 2020

Large Genetic Study Expands Links Between DNA Variations and Problematic Drinking

Posted: September 03, 2020

Researchers Discover Proteins in the Brain That Protect Synapses From Being Eliminated

Posted: August 20, 2020

Brainwave Study Reveals Oscillation Patterns That May Predict Transition to Psychosis

Posted: April 23, 2020

Genome Engineering Combined with Stem Cell Technology Provide Insights on Disruptions in Brain Development

Posted: March 31, 2020

Taking the Next Step in Understanding the Genetic Roots of Mental Illness

Connecting the Dots, From Genes to Brain Biology to Disorders

Posted: March 26, 2020

Progress is Reported on Research Exploring Use of Deep-Brain Stimulation for Psychosis, Schizophrenia

Posted: February 20, 2020

Maternal Inflammation Early in Pregnancy May Raise Offspring’s Psychosis Risk

Posted: January 16, 2020

New Approach to Lessen Negative Symptoms in Schizophrenia is Based on Brain Circuit Discovery

Posted: January 09, 2020

Higher Maternal Choline Levels in Pregnancy Had Protective Role in Infant Brain Development

Posted: November 21, 2019

Imaging Study Links Changes in Function and Structure of the Hippocampus in Early Psychosis

Posted: November 14, 2019

After 60 Years, Study Finds Children of Mothers with Bacterial Infections During Pregnancy Have Elevated Psychosis Risk

Posted: October 24, 2019

Study Links an Early-Life Abnormality in the Auditory Cortex with Vulnerability to Hallucinations in Schizophrenia

Posted: September 19, 2019

Low Levels of Cannabinoid Receptor in New Psychosis Patients Suggest a Possible Drug Target

Posted: August 01, 2019

A Way of Predicting if New Psychosis Patients Will or Won’t Respond to Standard Treatment

Posted: June 30, 2019

RESEARCH FOR RECOVERY: Advances in Cognitive Remediation: ‘Helping Schizophrenia Patients Who Need It Most’

Posted: June 27, 2019

A Rarely Studied Brain Structure Provides New Clues About Psychosis

Posted: June 13, 2019

Evidence Links Abnormally Formed Proteins With Schizophrenia Pathology in Some Patients

Posted: May 30, 2019

Research on Antioxidant Role in Schizophrenia and Psychosis Points to Possible Therapeutic Value of Compound Found in Broccoli

Posted: April 09, 2019

In a Comparison of Two Kinds of Cognitive Training, One Appeared to Help Schizophrenia Patients More

Posted: January 30, 2019

Adding Guanfacine Boosted Benefits of Cognitive Remediation Therapy in Schizophrenia Spectrum Disorder

Posted: January 14, 2019

Researchers Study ‘Background’ Mutations That Can Impact Schizophrenia and Autism

Posted: November 05, 2018

The Brain Continues to Develop in Young People With Schizophrenia

Posted: October 22, 2018

Computer-Delivered Cognitive Training Significantly Helped Schizophrenia Patients in Rehab Setting

Posted: October 17, 2018

A Revealing Genetic Comparison of Schizophrenia and Bipolar Disorder

Posted: October 09, 2018

Boosting Motivation and Cognitive Deficits in Mental Illness

Posted: September 11, 2018

Machine-learning Helped Identify Newly Diagnosed Schizophrenia Patients and Predicted Treatment Response

Posted: August 29, 2018

Medicinal Herb May Relieve Worsening Symptoms of Schizophrenia

Posted: August 13, 2018

“Disorganized Thinking” in Psychosis is Linked to Brain Processing Problem in Cerebellum

Posted: July 27, 2018

Study Suggests Cannabis Compound Can Make Schizophrenia Medication Less Effective

Posted: July 25, 2018

Folic Acid-Fortified Foods During Pregnancy May Support Child’s Brain Development After Birth

Posted: July 12, 2018

Genetic Variations Reveal Which Patients Will Have Cognitive Benefits From Antipsychotic Medications

Posted: June 26, 2018

Schizophrenia-Linked Genes Leave Developing Brains Vulnerable During Complicated Pregnancies

Posted: June 20, 2018

Impairments in Brain’s White Matter Linked to Core Cognitive Deficits in Schizophrenia

Posted: April 03, 2018

Large Gene Expression Study Sheds Light on Causal Factors in Five Brain Disorders

Posted: March 20, 2018

A 21st-Century Approach to Treating Psychosis and Other Adolescent Mental Health Disorders

Treating Psychosis Patients Early and Comprehensively Has Resulted in Improved Outcomes

Molecular Picture Points the Way to Better Antipsychotic Medications

Posted: March 12, 2018

NAC Medication Improves Working Memory in Schizophrenia and Bipolar Patients with Psychosis

Posted: February 26, 2018

Social Impairment Levels Remain Stable in Patients with Psychotic Disorders

Posted: February 05, 2018

Analysis Reveals Accelerated Rates at Which the Brain’s Gray and White Matter Deteriorate in Schizophrenia

Posted: November 28, 2017

Genome-Wide Studies Aid Investigation of Dual Diagnosis of Schizophrenia and Substance Use Disorder

Posted: November 07, 2017

Researchers Uncover Neural Circuit that Underlies Interest in Novelty

Posted: October 24, 2017

Studying Psychotic Symptoms in Marijuana Smokers at High Psychosis Risk

Posted: September 18, 2017

Research Shows ‘Exquisite’ Complexity of a Cell Network Regulating a Fear Circuit

Posted: August 29, 2017

New Calculator Helps Predict Risk of Developing Psychosis Across Diagnoses

Posted: July 18, 2017

New Technique Lets Researchers Watch Human Brain Circuits Begin to Wire-Up

Posted: June 26, 2017

Study Uncovers Role for Cerebellum in Cognitive Defects in Schizophrenia

Posted: June 05, 2017

New Class of Drugs Shows Promise for the Treatment of Schizophrenia in Animal Models

Posted: May 31, 2017

Study Reveals Weaker Brain Connections in Patients Who Did Not Receive Prompt Treatment for Psychosis

Posted: March 15, 2017

Diabetes Risk is Increased Even at the Start of Schizophrenia, Study Finds

Posted: February 22, 2017

Two New Studies Offer Alternative Explanation of Impaired Cognitive Function in Schizophrenia

Posted: February 15, 2017

Neurofeedback App Improves Early Cognitive Deficit in People with High Psychosis Risk

Posted: February 14, 2017

Study of Psychosis Relapses Among Schizophrenia Patients Suggests Preventive Potential of Frequent In-Person Check-ins

Posted: February 08, 2017

Sleep Disturbances Linked to Symptom Severity Among Those At High Risk for Psychotic Disorders

Posted: January 30, 2017

Research Indicates Cognitive Impairments are Early Symptoms of Psychotic Disorders

Posted: January 27, 2017

Mouse Study Reveals How Critical Connections Are Built in Early Brain

Posted: January 23, 2017

Blocking Overactive Enzyme Could Treat Schizophrenia Symptoms

Posted: January 19, 2017

New Research Defines Molecular Pathway That May Cause Psychosis in Some Types of Schizophrenia

Posted: January 10, 2017

New Way of Studying DNA as it’s Bundled in Cells Reveals New Schizophrenia Risk Genes

Posted: November 17, 2016

Researchers Catalog Subtle but Widespread Schizophrenia-Associated Differences in Gene Activity

Posted: November 02, 2016

Researchers Pinpoint Neurons That Cause and Maintain Wakefulness

Posted: September 30, 2016

New Technique Recreates Large-Scale Genetic Errors Linked to Neurodevelopmental Disorders

Posted: August 30, 2016

Study Finds Some Autism and Schizophrenia Related Genes May Also Be Involved in Bipolar Disorder

Posted: August 19, 2016

New Tool Calculates Patients’ Personal Psychosis Risk

Posted: July 27, 2016

Women Have More Gene Copy Number Variations Than Men, But This Doesn’t Increase Schizophrenia Risk as Expected

Posted: July 19, 2016

Doubt is Cast on the Contribution of Older Fathers’ Gene Mutations to Increased Mental Illness Risk in Their Children

Posted: July 13, 2016

Infections During Pregnancy Could Cause Developmental Disorders in Children

Posted: June 21, 2016

Prenatal Nicotine Exposure Raised Odds of Schizophrenia in Children

Posted: June 09, 2016

Gut Bacteria's Vital Role in Prefrontal Cortex, Brain's White Matter

Posted: May 24, 2016

Could Anti-Inflammatory Meds Prevent Immune-Linked Brain Disorders?

Posted: May 16, 2016

Blood Markers Indicate High Inflammation Levels in People with Schizophrenia, Bipolar Disorder and Depression

Posted: May 05, 2016

Researchers Reverse Cognitive and Behavioral Deficits in New Mouse Model for Schizophrenia

Posted: May 02, 2016

How Genes May Help Determine Response to Antipsychotic Medications

Posted: May 01, 2016

Testing a Simple Strategy To Prevent Schizophrenia via Dietary Supplements

New Biotypes Classify Psychosis Cases According to Measurable Biological Features

Onset of Psychotic Disorders Differs Among Ultra-High Risk Groups

Posted: April 29, 2016

Children’s Schizophrenia Risk Correlated with Their School Performance vs. Family Members

Posted: April 12, 2016

New Experiments Reveal Brain Circuitry Behind Inability to Experience Pleasure

Posted: April 05, 2016

Immune Activity During Pregnancy Tied to Neuronal Defects, Anxiety, and Cognitive Impairments

Posted: March 21, 2016

A Role for Spontaneous Mutations in the Development of Childhood-Onset Schizophrenia

Posted: March 07, 2016

Abnormalities in a Highly Duplicated Genome Region May Reveal Continuities in Symptoms of Schizophrenia and Autism

Posted: January 28, 2016

A Milestone in the Search for Schizophrenia’s Causes

Posted: January 15, 2016

Overactive Immune Cells Precede Schizophrenia Diagnosis

Posted: January 11, 2016

Animal Study Offers New Clues to the Genetics of Schizophrenia

Posted: December 01, 2015

Connectivity Problems May Indicate Which Individuals are at Greatest Risk for Schizophrenia

Posted: November 20, 2015

Imaging Studies Reveal Affected Brain Regions in Schizophrenia

Posted: November 06, 2015

New Insights into the Genetic Basis of Schizophrenia

Posted: October 22, 2015

Hopeful News on Comprehensive Team Treatment of Early Psychosis

Posted: August 26, 2015

Non-Invasive Stimulation Reworks Brain Waves, Improves Cognition

Posted: July 31, 2015

Genes Linked to Abnormal Brain Waves in Schizophrenia, Psychotic Bipolar Disorder

Posted: July 20, 2015

New Compounds Show Promise in Treating Schizophrenia Symptoms

Posted: July 15, 2015

Can Smoking Tobacco Lead to Schizophrenia?

Posted: July 07, 2015

Schizophrenia-Related Gene Mutation Impairs Fear Processing in Mice

Posted: July 06, 2015

Genetic and Brain Structure Abnormalities Linked in Schizophrenia

Posted: June 26, 2015

Innovative Analysis Finds Unique Brain Structure Patterns in People with Schizophrenia

Posted: June 23, 2015

Brain Connectivity Problems Linked with Psychotic Disorders are Present in Youth with Less Severe Symptoms

Posted: June 16, 2015

Large Study Confirms Major Hypotheses in Schizophrenia Research

Posted: June 09, 2015

Estrogen Drug Improves Cognition in Schizophrenia Patients

Posted: June 01, 2015

Large-Scale Gene Mutation Disrupts Brain Development During Key Period

Posted: May 18, 2015

Gene Associated With Cognitive Deficits a Possible Target For Drug Treatment

Posted: May 11, 2015

Genetic Disorder Points to Cellular Communication Problems in Schizophrenia

Posted: April 24, 2015

Tracing a Circuit Between Two Brain Areas Points To New Schizophrenia Treatment Targets

Posted: April 21, 2015

Three-Month Dosage of Injectable Antipsychotic Prevents Return of Schizophrenia Symptoms

Posted: April 13, 2015

Neurosteroid Treatment Reduces Schizophrenia-Like Symptoms in Mice

Posted: April 10, 2015

Understanding the Link Between White Matter Abnormalities and Schizophrenia Symptoms

Posted: April 06, 2015

Imaging Reveals Specific Brain Circuit Differences in a Subtype of Schizophrenia

Posted: March 23, 2015

Early Cognitive Decline Predicts Later Psychosis in Children With a DNA Deletion Syndrome

Posted: March 20, 2015

Digging Deeper into the Cause of Cognitive Deficits in Schizophrenia

Posted: March 17, 2015

New Clues About How Healthy Circuits Form in Developing Brains

Posted: March 10, 2015

New Clues About a Brain Receptor, a Neurotransmitter, and Schizophrenia

Posted: February 05, 2015

Study Finds Brain-Wave Increase in People With Schizophrenia

Posted: January 30, 2015

Multiple Psychiatric illnesses Share the Same Perturbed Biological Pathways

Posted: January 22, 2015

To Better Understand Mental Disorders, Researchers Reverse Engineer Schizophrenia “in a Dish”

Genetic signals emerging on schizophrenia risk, targeting the d1 dopamine receptor to improve working memory in schizotypal personality disorder.

Posted: January 21, 2015

Early-Stage Schizophrenia Associated With Increased Prefrontal Cortex Connectivity That is Reversed Following Treatment

Posted: January 20, 2015

Wiring Anomalies in the Fetal Brain Due To a Faulty Protein May Be a Causal Factor in Schizophrenia

Posted: January 08, 2015

New Pharmaceutical Approach Shows Potential Benefit in More Narrowly Targeting Antipsychotic Medicines

Posted: January 07, 2015

Problems with Attention Traced to Specific Brain Circuit

Posted: December 18, 2014

Researchers Discover New Regions of the Genome That Contribute to the Risk of Schizophrenia

Posted: December 09, 2014

IQ Study Finds Environmental and Genetic Factors in Schizophrenia Risk

Posted: December 03, 2014

Psychotic Symptoms in Young People Foreshadow Later Problems

Posted: November 22, 2014

Developing Risk Profiles for Schizophrenia

Posted: November 05, 2014

The Life of a Spine: Neuron Communication and Schizophrenia

Posted: October 23, 2014

What Causes the Placebo Effect in Clinical Trials of Antipsychotic Medications?

Posted: October 16, 2014

Study Offers New Insight into What Causes Learning Impairment in Schizophrenia

Posted: October 10, 2014

World Mental Health Day: “Living with Schizophrenia”

Posted: September 29, 2014

International Collaborative Effort Develops the Beginnings of a Blood Test for Psychosis

Posted: September 25, 2014

Stem Cell Technology Offers New Insight into Brain Mechanisms Underlying Schizophrenia

Posted: September 18, 2014

Bolstering Reading Skills Could Improve Outcomes in Schizophrenia

Posted: September 16, 2014

Electroconvulsive Therapy, with Clozapine, Shows Promise for Patients with Treatment-Resistant Schizophrenia

Posted: September 10, 2014

Finding Common Roots Across Spectrum of Psychosis May Improve Early Intervention Techniques

Posted: September 08, 2014

Congratulations to Mary-Claire King, Ph.D., Foundation Scientific Council Member, for 2014 Lasker Award!

Posted: September 04, 2014

Psychosocial Training Shows Promise as Supplemental Treatment for Schizophrenia

Posted: September 02, 2014

Resting State Brain Imaging Points to Differences in Early- and Late-Stage Schizophrenia

Posted: August 27, 2014

NARSAD Grantee Discovers Clues to New Pathways for Treatment of Schizophrenia

Posted: August 25, 2014

Can Antioxidants Help Prevent and /or Treat Symptoms of Schizophrenia?

Posted: August 21, 2014

With New Technology, Researchers See How Faulty Human Brain Cells Develop

Posted: August 15, 2014

Foundation-Funded Researcher Identifies Brain “Switchboard” that May Malfunction in Autism, Schizophrenia

Posted: August 08, 2014

Foundation-Supported Research Finds “Helper” Cells in Brain Actually Support Memory Function

Posted: July 25, 2014

“Reprogramming” of Genes Causes Some Symptoms of Mental Illness—May Be Reversible

Posted: July 22, 2014

Advancing Genetics Offer Promise for Developing Risk Profiles, Better Treatments for Schizophrenia

Posted: July 17, 2014

Maternal Infection, Inflammation during Pregnancy Linked to Baby's Risk for Schizophrenia

Posted: July 15, 2014

Stem Cell Technology Offers Rare Inside View of Brain Development and Schizophrenia

Posted: July 07, 2014

New Global Study Quantifies Risk of Mental Illness from Genetic Deletion Syndrome

Posted: July 03, 2014

Dr. Sanjay Gupta of CNN Quotes Foundation President in Articles on Schizophrenia

Posted: July 02, 2014

Gender Differences in the Adolescent Brain that May Link to Mental Illness

Posted: July 01, 2014

New Technique Identifies Genetic Underpinning of Disrupted Brain Connectivity in Schizophrenia

Posted: June 20, 2014

Researchers Complete Picture of How Brain Mechanism Linked to Depression, Schizophrenia Functions

Posted: June 19, 2014

Gene Linked to Bipolar Disorder, Schizophrenia Plays Key Role in Brain Development

Posted: June 17, 2014

NARSAD Grantees Advance Knowledge of Genetics and Early Brain Development in Schizophrenia

Posted: June 05, 2014

Released Today: New Insight into Root Cause of Auditory Hallucinations in Schizophrenia

Posted: June 02, 2014

Foundation-Funded Research Suggests Prenatal Beginnings of Schizophrenia, Could Aid Early Diagnosis

Posted: May 30, 2014

Genetic Sequencing Technology Helps Identify Mutations Linked to Development of Schizophrenia

Posted: May 19, 2014

Transplanting Brain Cells, Researchers Discover Potential Approach to Treat or Prevent Psychosis

Posted: May 08, 2014

Novel Approach Leads to Discovery of Disruption in Brain Connectivity in Schizophrenia

Posted: April 30, 2014

Study on Genetic Variability in Schizophrenia May Improve Prevention and Treatment Strategies

Posted: April 17, 2014

Foundation-Supported Research Advances Technology to Study Developmental Mechanisms of Schizophrenia

Posted: April 10, 2014

Misfiring Brain Signals in Schizophrenia Distort View of Reality

Posted: April 07, 2014

NARSAD Grantee Finds Experimental Compound Reverses Schizophrenia Symptoms in Mice

Posted: March 19, 2014

Brain Mapping Furthers Understanding of Why Imitation is Difficult in Schizophrenia

Posted: March 17, 2014

Scalp EEG Test May Be Able to Predict Future Psychosis

Posted: March 10, 2014

Genetic Analysis Offers New Insight into Memory Impairment in Schizophrenia

Posted: March 07, 2014

NARSAD Grantee Develops 3-D Picture of Protein Important in Schizophrenia

Posted: March 05, 2014

Integrated Approaches to Develop Improved Schizophrenia Therapies

Fine-tuning the circuitry in the brain and intervening early on: exciting next-generation treatment possibilities.

Posted: February 13, 2014

Crossed Wires in the Brain as Potentially Reversible Cause of Schizophrenia

Posted: January 27, 2014

New Understanding of Genetics Behind Schizophrenia From International, Collaborative Research Efforts

Effective brain communication impeded by “new” genetic mutations, progress in identifying sets of genes linked to schizophrenia, solving the schizophrenia puzzle, what makes some genes disrupt brain development, next generation therapies for schizophrenia: from specific genetic mutations to targeting repair pathways.

Posted: January 17, 2014

2013 Baer Prizewinner With a Dream: "To Re-Connect the Soul to the Mind... the Soul to the Brain" - Watch Video

Posted: January 13, 2014

New Technology Assesses Brain Plasticity, May Help with Schizophrenia, Depression

Posted: January 09, 2014

New Research Shows “Jumping Genes” Could Contribute to Schizophrenia

Posted: January 02, 2014

2013 NARSAD Grant Supports Discovery of Genetic Overlap Between Schizophrenia and Cognitive Ability

Posted: December 17, 2013

NARSAD Grant Furthers Exploration of Link between Older Fathers and Mental Illness

Posted: December 16, 2013

NARSAD Young Investigator Grantee Invents New Technology to Study Brain Plasticity

Posted: December 12, 2013

Chicken or Egg? New Research Shows Men and Women’s Brains are Wired Differently

Posted: December 02, 2013

Why do Antibodies Found in the Blood Only Sometimes Link to Neuropsychiatric Illness?

Posted: November 22, 2013

Discovery of First Genetic Protective Factor for Schizophrenia

Posted: October 25, 2013

Esteemed Schizophrenia Researcher, Marc G. Caron, Awarded with 2013 Lieber Prize

Posted: October 24, 2013

Electrical Stimulation Can Improve Cognitive Performance―May Help in Schizophrenia, Bipolar Disorder

Posted: October 23, 2013

Founding Foundation Scientific Council Member Awarded International Mental Health Prize

Posted: October 22, 2013

State of MD Supports Foundation Scientific Council Member’s Early Intervention in Psychosis Program

Researchers Find Way to Increase Neuroplasticity and Treat “Negative” Symptoms of Schizophrenia

Posted: October 21, 2013

Looking for What May Cause Disordered Thinking (“Cognitive Deficits”) in Schizophrenia

Posted: October 08, 2013

Defining Psychotic Disorders―Mood Disorders and Schizophrenia―by Symptom Course and Long-Term Outcome

Posted: October 04, 2013

Pre-Term Birth Associated with Higher Risk of Mental Illness, But Also for Siblings

Posted: September 26, 2013

Long-Term Study of Children Shows Progressive Nature of Thinking Difficulties in Schizophrenia

Posted: August 15, 2013

New Schizophrenia Genes Discovered Through Innovative Genetic Sequencing Approach

Serotonin discovery via x-ray crystallography points toward more precise treatments.

Posted: August 02, 2013

Parent’s Diet May Impact Child’s Mental Health Shows NARSAD Grantee Generational Study

Posted: July 18, 2013

Genetic Sequencing Technology Helps Uncover New Potential Causes of Schizophrenia

Posted: July 16, 2013

Foundation Grantees Link Oxidative Stress with Mental Illness Risk Gene

Posted: July 05, 2013

Brain & Behavior Research Foundation-Funded Study Links Schizophrenia, Inflammation & Bacteria

Posted: July 03, 2013

Is Smoking Self Medication? New NARSAD Grant Research Provides Critical Insights

Posted: July 01, 2013

NARSAD Grant-Funded Discoveries Offer New Treatment Target for Schizophrenia

Posted: June 27, 2013

NARSAD Grantees Discover Potential for Treatment to Reverse Schizophrenia Symptoms

Posted: June 24, 2013

NARSAD Grantee Co-Leads Mammoth Effort to Dissect Mental Illness Risk Gene

Posted: June 20, 2013

NARSAD Grant-Funded Research Helps Identify Mechanisms To Improve Schizophrenia Treatment

Posted: June 14, 2013

Discovery Using Optogenetics May Help Fine-Tune Treatments for Schizophrenia Symptoms

Posted: June 10, 2013

New Computational Method Helps Decode Complex Circuitry of the Brain

Posted: June 07, 2013

Cutting-Edge Stem Cell Technology Offers New Insight Into Development of Schizophrenia

Posted: June 06, 2013

Relapse & Antipsychotic Treatment in Schizophrenia Change Brain

Posted: May 30, 2013

NARSAD Grantees Reverse Schizophrenia Symptoms in Adult Animals

Posted: May 21, 2013

Damaged Protective ‘Net’ May Cause Malfunction in Brain Cells in Schizophrenia

Posted: May 13, 2013

FDA Expedites New Psychosis Treatment Developed by Scientific Council Member

Posted: May 09, 2013

A New Window to Study Mental Illness: Stem Cells Converted to Brain Cells

Posted: May 02, 2013

The Nose May Know: Study Finds New Potential Way to Diagnose Schizophrenia

Posted: April 29, 2013

Foundation-Funded Study Identifies Schizophrenia Early Warning Sign

Posted: April 17, 2013

NARSAD Grantee Maps Brain Navigation – Insights May Help Treat Schizophrenia

Posted: April 18, 2013

How Studies With Children Are Helping Identify Early Developmental Links to Mental Illness

Intervening in early psychosis with computer-based brain training.

Posted: April 16, 2013

Understanding Healthy Brain Function Furthers Progress in Identifying Causes of Schizophrenia

Posted: April 03, 2013

New Schizophrenia Genes Discovered Through Innovative Genetic Sequencing

Posted: March 29, 2013

NARSAD Grantees Link Altered Brain Activity to Schizophrenia Cognitive Symptoms

Posted: March 21, 2013

New Technology Enables New Insights Pointing toward Safer Schizophrenia Medications

Posted: March 14, 2013

NARSAD Grant-Funded TMS Now Found Effective in Treating Schizophrenia Symptoms

Posted: March 12, 2013

NARSAD Grantee Discovers Predictor of Psychosis in Bipolar Disorder, Schizophrenia

Posted: March 06, 2013

Single Gene Plays Defining Role in Schizophrenia Symptoms and Outcomes

Posted: March 01, 2013

Recovery Interventions that Promote Productive Lives

Posted: February 25, 2013

NARSAD Grantee Helps Uncover Schizophrenia Warning Sign

Posted: February 19, 2013

NARSAD Grantee ‘2012 Editor’s Choice’ for Work on Recovery from Schizophrenia

Posted: February 12, 2013

Discovery Links Inflammation to Schizophrenia Onset, May Aid Early Intervention/Prevention

Posted: February 07, 2013

Foundation Grantees Develop Brain Atlas to Aid Understanding of Autism, Schizophrenia

Posted: February 01, 2013

Identifying What Keeps Electrical Impulses in the Brain Balanced—Linked to Schizophrenia

Posted: January 25, 2013

NARSAD Grant-Funded Research Identifies New Genetic Link to Development of Schizophrenia

Posted: January 21, 2013

Foundation-Funded Research Helps Identify How Adolescent Stress Can Cause Mental Illness

Posted: January 18, 2013

Schizophrenia Research Forum Features Paper with Discoveries on Genetic Deletion Syndrome

Posted: January 15, 2013

Released Today: Supplement Shows Promise for Preventing Schizophrenia

Posted: January 14, 2013

Learning About Individual Genetics Alleviates Suffering for Patients with Schizophrenia

Posted: December 27, 2012

2012 Highlights: A Sampling of NARSAD Grants at Work

Posted: December 17, 2012

Cells and Circuits: Neurotransmission with a Focus on Dopamine

Cognitive remediation activates neuroplasticity and improves social cognition in schizophrenia.

Posted: November 30, 2012

NARSAD Grantees Lead Study Pointing To Novel Pathways for Treatment of Schizophrenia

Posted: November 29, 2012

2008 Lieber Prizewinner Wins 2013 Grawemeyer Award for Schizophrenia Research

Posted: November 27, 2012

NARSAD Grant-Funded Research Furthers Understanding of What Makes Us Human

Posted: November 26, 2012

Dr. Walters Receives Sidney R. Baer, Jr. Prize for Innovative Schizophrenia Research

Posted: November 02, 2012

Dr. Michael Owen Recognized for Outstanding Achievement in Schizophrenia Research

Narsad grant-funded research identifies where empathy originates in the brain.

Posted: November 01, 2012

Prestigious Lieber Prize for Schizophrenia Research Goes to Dr. Michael O’Donovan

Posted: October 15, 2012

NARSAD Grantee Identifies New Pathway to Treat Schizophrenia

Posted: October 11, 2012

NARSAD Grantees Identify New Genetic Mutations that Cause Schizophrenia

Posted: September 24, 2012

Premature Birth Heightens Risk for Mental Illness

Comprehensive identification of key genetic players in schizophrenia, a natural laboratory: using an isolated population to study schizophrenia genes, translating epigenetics into novel therapies for autism and schizophrenia.

Posted: August 23, 2012

NY Times: New Study Confirming Risk of Autism and Schizophrenia Increases with Father’s Age

Posted: August 07, 2012

Creating a New Window to Study Synaptic (Dys)Function in Brain and Behavior Disorders

Posted: July 20, 2012

NARSAD Grantee Leads Team That Links Two Risk Factors for Schizophrenia

Posted: July 05, 2012

NARSAD Grant-funded Research Finds Links Between Schizophrenia, Bipolar and Autism

Posted: July 03, 2012

NARSAD Grantee Discusses Innovative Work to Understand and Better Treat Mental Illnesses

Posted: June 28, 2012

FDA to Evaluate Computer-Based Treatment for Cognitive Symptoms in Schizophrenia

Posted: June 19, 2012

NARSAD Grant-Funded Research Identifies Genetic Links in Weight Gain from Antipsychotics

Posted: June 04, 2012

NARSAD Grant-Funded Research Finds Premature Birth Increases Risk for Mental Illness

Posted: May 17, 2012

NARSAD Grantee Leads Breakthrough Research that Identifies the Genetic Code of Schizophrenia

Posted: March 29, 2012

New Discovery On Link Between Early Life Stress and Genetic Susceptibility in Schizophrenia

Posted: March 20, 2012

New Computer Program Improves Behavioral Symptoms and Brain Activity in Schizophrenia

Posted: March 12, 2012

25 Years of Outstanding Schizophrenia Research: The Lieber Prize

Posted: February 29, 2012

NARSAD Grantees Make Breakthrough to Improve Cognition in Schizophrenia

Posted: February 07, 2012

Scientific Council Member Outlines the Progress in – and Need for – Mental Health Research

Posted: January 20, 2012

SC Member Makes Discovery About Teen Susceptibility to Depression and Schizophrenia

Posted: January 19, 2012

A New, Quick Approach to Predict Future Course of Psychosis

Posted: January 06, 2012

Foundation-funded Discovery: Early Childhood Immigration Linked to Psychotic Disorders

Posted: January 05, 2012

NARSAD Grantee Makes New Discovery About Brain Malfunction in Schizophrenia

Posted: December 30, 2011

Basic Research and Novel Therapeutic Treatments Pave the Road to Cures for Mental Illness

Posted: December 05, 2011

Foundation Web-based Schizophrenia Research Forum Honored by ACNP

Posted: November 30, 2011

A Scientist Writes About Autism, Schizophrenia and their Causes

Posted: November 29, 2011

Foundation-funded Investigator Honored for Mental Illness Research Achievements

Posted: November 21, 2011

World-Renowned Investigator’s Personal Connection to Schizophrenia

Posted: November 18, 2011

BBC “Mental Health Revolution” Features Foundation-Funded Psychiatry Research

Posted: November 15, 2011

Coping with Psychosis: Using CBT to Manage Persistent Symptoms

‘father of cbt’ demonstrates its effectiveness treating low-functioning schizophrenia patients, genome-wide studies identify 11 new genetic links to schizophrenia and bipolar disorder.

Posted: November 09, 2011

Breakthrough in Schizophrenia Research by Foundation's 2011 Outstanding Prizewinner

Posted: November 03, 2011

Scientific Council Member Leads Effort that Reprograms Skin Cells to Grow Brain Cells in Lab

Brain & behavior research foundation scientific council member discovers key dopamine receptor structure.

Posted: October 24, 2011

New Understanding of Autism and Schizophrenia in Adolescence?

Posted: October 10, 2011

Outstanding Achievement Prizewinner Makes Discovery, Progressing Research for New Schizophrenia Treatments

Posted: October 06, 2011

NY Times Features Breakthrough in Treatment of Schizophrenia by Foundation-funded Scientist

Posted: October 03, 2011

A “GPS” System for Brain Cells is Created by 2011 NARSAD Distinguished Investigator Grantee

Posted: September 26, 2011

Understanding Why Identical Twins Are Not Carbon Copies in Mental Illness

Posted: September 22, 2011

Foundation Honors Scientists For Outstanding Achievements in Mental Illness Research

Posted: September 15, 2011

The Saturday Evening Post features NARSAD Grantees’ breakthrough insight on link between maternal infection and mental illness

Posted: August 26, 2011

NARSAD Distinguished Investigator Demonstrates Working Memory Can Be Restored in Elderly Primates

Foundation-funded discovery points toward genetic networks that predispose to schizophrenia.

Posted: July 26, 2011

Foundation-funded Study Supports Hypothesis That Davunetide Prevents Cortical Thinning in Brains of Schizophrenia Patients

Posted: May 26, 2011

Brain and Behavior Research Foundation-Funded Study Provides Explanation for Why People with Schizophrenia Have Difficulty with Social Cues

Posted: April 11, 2011

Leading Researcher Uses Innovative Ways To Improve Treatments

Twenty-year career leading discoveries into the complex circuitry of the brain points toward more effective treatments, foundation-funded discovery of new schizophrenia gene could lead to new diagnostic and therapy possibilities.

Posted: March 23, 2011

NARSAD Investigator Makes Major Breakthrough in Understanding Brain Function

Posted: March 01, 2011

Stem Cells Offer New Insight into Helping the Brain Regenerate

Narsad-funded research breakthrough could improve treatment of schizophrenia.

Posted: February 17, 2011

Upcoming Conference: “Advancing Drug Discovery for Schizophrenia”

Posted: February 07, 2011

Hearing from NARSAD Young Investigators (Part 2)

Posted: February 04, 2011

The NARSAD Feed: NARSAD-Funded Discoveries, Economics of (Mental) Health Care Reform, Meditation and Your Brain

Posted: February 01, 2011

NARSAD Supports Innovative Technologies That Improve Treatment of Mental Illness

Narsad scientific council member discovers key dopamine receptor structure.

Posted: January 03, 2011

NARSAD-Funded Research Suggests Brain Scans Could Predict Onset of Schizophrenia

Posted: December 13, 2010

A very grand vision: “We will discover the causes of mental illnesses so that we can someday develop prevention protocol to keep people from developing these illnesses”

Posted: November 01, 2010

NARSAD-Funded Research Identifies New Gene Candidate for Schizophrenia

Leading the way - a brilliant mind in schizophrenia research sees cause for optimism, can studies of substance abuse in schizophrenia lead to better medications.

Posted: October 01, 2010

NARSAD Researcher Makes Progress Toward His Goal of Prevention of Schizophrenia and Other Mental Illnesses

Posted: September 01, 2010

NARSAD Researcher Makes Discovery in Brain’s Decision-Making Process

Posted: April 10, 2010

Schizophrenia: Is Recovery Possible?

‘retraining the brain’ in patients with schizophrenia.

Posted: April 01, 2010

Mary-Claire King and Judith Rapoport: New Hope From Discovery of Rare Genetic Mutations in Schizophrenia

Aaron beck: reducing schizophrenia’s negative symptoms.

Posted: April 25, 2008

Discovery of Important Genetic Links to Schizophrenia

Posted: November 01, 2003

Identification of Genes Associated with Schizophrenia

Posted: April 01, 1996

Discovery of Novel Gene-Regulating Molecule (Transcription Factor) that Mediates Effects of Stress

Posted: December 01, 1989

Approval of Clozapine to Treat Resistant Schizophrenia

Key figures.

3.5 million adults (1.1%) of the US Adult population live with schizophrenia*

* Source: National Institute of Mental Health

More than 21 million people worldwide are affected by schizophrenia*

* Source: World Health Organization (WHO) 

Featured Tweet

New risk genes for #schizophrenia have been discovered by studying DNA in highly compressed bundles. TWEET

Meet a Researcher

Mary-Claire King, Ph.D.

American Cancer Society Professor

Professor, Medical Genetics

Professor, Genome Sciences

Adjunct Professor, Epidemiology

Department of Medicine and the Department of Genome Sciences

University of Washington-Seattle

Scientific Council Member (Joined 2009)

2006 Distinguished Investigator Grant

Ask an Expert

Huda Akil, Ph.D.

Gardner Quarton Distinguished University Professor of Neuroscience and Psychiatry

Co-Director, Molecular and Behavioral Neuroscience Institute

2007 Goldman-Rakic Prize for Outstanding Achievement in Cognitive Neuroscience

In your work with the Pritzker Neuropsychiatric Research Consortium, have you uncovered any new genes that you think might be related to mental illnesses besides major depression?

• More Questions

Learn More About the Foundation

The Brain & Behavior Research Foundation is a global nonprofit organization focused on improving the understanding, prevention and treatment of psychiatric and mental illnesses.

Beginning in 1987, the Brain & Behavior Research Foundation was providing seed money to neuroscientists to invest in “out of the box” research that the government and other sources were unwilling to fund. Today, Brain & Behavior Research Foundation is still the leading, private philanthropy in the world in this space.

Meet the people who make up the Brain & Behavior Research Foundation. Our staff of experts, passionate Board of Directors, and Scientific Council which includes Nobel prize winners and chairs of psychiatric departments around the world.

Annual Report & Financials

We take our responsibility to our donors seriously and believe that our financial operations must be transparent. We're proud to say that 100% of your contribution for research is invested directly in research grants.

Frequently Asked Questions about the Brain & Behavior Research Foundation.

The latest news on brain and behavior research and issues that matter most to you.

Donations are welcome

100% of every dollar donated for research is invested in our research grants. Our operating expenses are covered by separate foundation grants.

The Brain & Behavior Research Foundation is a 501(c)(3) nonprofit organization, our Tax ID # is 31-1020010.

Study uncovers cell type-specific genetic insights underlying schizophrenia

Schizophrenia is a complex disease with variable presentations, and the diverse nature of this mental health disorder has made understanding the mechanisms that cause the disease, and subsequently developing effective treatments, especially challenging. In a new study, published May 23 is Science , a team led by McLean Hospital researchers used comprehensive genetic and cellular analyses to shed new light on the intricate molecular mechanisms underlying schizophrenia. Their new work provides a map for how the genes known to increase risk of schizophrenia affect specific cells within the brain.

"We discovered which cell types express genes associated with schizophrenia risk differently, which biological functions are impacted within those cells, and which transcription factors are important for these changes," explained lead and co-corresponding author, W. Brad Ruzicka MD, PhD, director of the Laboratory for Epigenomics in Human Psychopathology at McLean Hospital. "This understanding will allow future treatments to be tailored to specific genes and cell types, as well as individuals with schizophrenia."

Schizophrenia affects approximately 24 million people, or 1 in 300 people, worldwide, according to the World Health Organization.

For the new study, a multi-center team of researchers conducted a comprehensive single-cell analysis of transcriptomic changes in human prefrontal cortex, examining postmortem brain tissue from 140 individuals across two independent cohorts. Their analyses included more than 468,000 cells.

They uncovered unprecedented insights into the cellular basis of schizophrenia, linking genetic risk factors to specific neuronal populations. Specifically, the researchers found that excitatory neurons emerged as the most affected cell group, with transcriptional changes implicating neurodevelopment and synapse-related pathways. Additionally, they found that known genetic risk factors for schizophrenia converge on alterations in specific neuronal populations, highlighting the interplay between rare and common genomic variants. Through transcriptomic analysis, two distinct subpopulations of individuals with schizophrenia were identified, marked by the expression of specific excitatory and inhibitory neuronal cell states.

The new study suggests potential links between schizophrenia pathology and processes such as neurodevelopment, synaptic signaling, and transcriptional regulation, implicating key transcriptional regulators associated with both schizophrenia and neurodevelopmental disorders.

The study's authors anticipate that insights gleaned from this research could pave the way for targeted interventions and personalized treatments for schizophrenia, potentially improving clinical outcomes for individuals affected by this debilitating and often disabling disorder.

The research team is now working to expand on these findings by investigating other regions of the brain and the molecular impact of other psychiatric diseases such as bipolar disorder. They are also pursuing another dimension of complexity in this system by investigating isoform expression of implicated genes and how these cell type-specific gene expression changes lead to functional and potentially druggable changes in the protein space.

"This work advances understanding of schizophrenia pathophysiology at greater detail across both the complex landscape of cells within the brain, and the diverse experiences of people with this disease," said Ruzicka, who is also associate medical director of Harvard Brain Tissue Resource Center at McLean, and an assistant professor of Psychiatry at Harvard Medical School. "Our increased mechanistic understanding of schizophrenia provides avenues for future research to unravel the genetic and environmental underpinnings of this complex disease so we can provide our patients better care."

• Mental Health Research
• Personalized Medicine
• Nervous System
• Brain Tumor
• Schizophrenia
• Mental Health
• Disorders and Syndromes
• Stem cell treatments
• Adult stem cell
• Positron emission tomography
• COX-2 inhibitor
• Dopamine hypothesis of schizophrenia
• Personalized medicine

Story Source:

Materials provided by McLean Hospital . Note: Content may be edited for style and length.

Journal Reference :

• W. Brad Ruzicka, Shahin Mohammadi, John F. Fullard, Jose Davila-Velderrain, Sivan Subburaju, Daniel Reed Tso, Makayla Hourihan, Shan Jiang, Hao-Chih Lee, Jaroslav Bendl, Georgios Voloudakis, Vahram Haroutunian, Gabriel E. Hoffman, Panos Roussos, Manolis Kellis, Schahram Akbarian, Alexej Abyzov, Nadav Ahituv, Dhivya Arasappan, Jose Juan Almagro Armenteros, Brian J. Beliveau, Sabina Berretta, Rahul A. Bharadwaj, Arjun Bhattacharya, Lucy Bicks, Kristen Brennand, Davide Capauto, Frances A. Champagne, Tanima Chatterjee, Chris Chatzinakos, Yuhang Chen, H. Isaac Chen, Yuyan Cheng, Lijun Cheng, Andrew Chess, Jo-fan Chien, Zhiyuan Chu, Declan Clarke, Ashley Clement, Leonardo Collado-Torres, Gregory M. Cooper, Gregory E. Crawford, Rujia Dai, Nikolaos P. Daskalakis, Amy Deep-Soboslay, Chengyu Deng, Christopher P. DiPietro, Stella Dracheva, Shiron Drusinsky, Ziheng Duan, Duc Duong, Cagatay Dursun, Nicholas J. Eagles, Jonathan Edelstein, Prashant S. Emani, Kiki Galani, Timur Galeev, Michael J. Gandal, Sophia Gaynor, Mark Gerstein, Daniel H. Geschwind, Kiran Girdhar, Fernando S. Goes, William Greenleaf, Jennifer Grundman, Hanmin Guo, Qiuyu Guo, Chirag Gupta, Yoav Hadas, Joachim Hallmayer, Xikun Han, Natalie Hawken, Chuan He, Ella Henry, Stephanie C. Hicks, Marcus Ho, Li-Lun Ho, Yiling Huang, Louise A. Huuki-Myers, Ahyeon Hwang, Thomas M. Hyde, Artemis Iatrou, Fumitaka Inoue, Aarti Jajoo, Matthew Jensen, Lihua Jiang, Peng Jin, Ting Jin, Connor Jops, Alexandre Jourdon, Riki Kawaguchi, Joel E. Kleinman, Steven P. Kleopoulos, Alex Kozlenkov, Arnold Kriegstein, Anshul Kundaje, Soumya Kundu, Cheyu Lee, Donghoon Lee, Junhao Li, Mingfeng Li, Xiao Lin, Shuang Liu, Jason Liu, Jianyin Liu, Chunyu Liu, Shuang Liu, Shaoke Lou, Jacob M. Loupe, Dan Lu, Shaojie Ma, Liang Ma, Michael Margolis, Jessica Mariani, Keri Martinowich, Kristen R. Maynard, Samantha Mazariegos, Ran Meng, Richard M. Myers, Courtney Micallef, Tatiana Mikhailova, Guo-li Ming, Emma Monte, Kelsey S. Montgomery, Jill E. Moore, Jennifer R. Moran, Eran A. Mukamel, Angus C. Nairn, Charles B. Nemeroff, Pengyu Ni, Scott Norton, Tomasz Nowakowski, Larsson Omberg, Stephanie C. Page, Saejeong Park, Ashok Patowary, Reenal Pattni, Geo Pertea, Mette A. Peters, Nishigandha Phalke, Dalila Pinto, Milos Pjanic, Sirisha Pochareddy, Katherine S. Pollard, Alex Pollen, Henry Pratt, Pawel F. Przytycki, Carolin Purmann, Zhaohui S. Qin, Ping-Ping Qu, Diana Quintero, Towfique Raj, Ananya S. Rajagopalan, Sarah Reach, Thomas Reimonn, Kerry J. Ressler, Deanna Ross, Joel Rozowsky, Misir Ruth, Stephan J. Sanders, Juliane M. Schneider, Soraya Scuderi, Robert Sebra, Nenad Sestan, Nicholas Seyfried, Zhiping Shao, Nicole Shedd, Annie W. Shieh, Joo Heon Shin, Mario Skarica, Clara Snijders, Hongjun Song, Matthew W. State, Jason Stein, Marilyn Steyert, Thomas Sudhof, Michael Snyder, Ran Tao, Karen Therrien, Li-Huei Tsai, Alexander E. Urban, Flora M. Vaccarino, Harm van Bakel, Daniel Vo, Brie Wamsley, Tao Wang, Sidney H. Wang, Daifeng Wang, Yifan Wang, Jonathan Warrell, Yu Wei, Annika K. Weimer, Daniel R. Weinberger, Cindy Wen, Zhiping Weng, Sean Whalen, Kevin P. White, A. Jeremy Willsey, Hyejung Won, Wing Wong, Hao Wu, Feinan Wu, Stefan Wuchty, Dennis Wylie, Siwei Xu, Chloe X. Yap, Biao Zeng, Pan Zhang, Chunling Zhang, Bin Zhang, Jing Zhang, Yanqiong Zhang, Xiao Zhou, Ryan Ziffra, Zane R. Zeier, Trisha M. Zintel. Single-cell multi-cohort dissection of the schizophrenia transcriptome . Science , 2024; 384 (6698) DOI: 10.1126/science.adg5136

Cite This Page :

Explore More

• Redefining Magnetism
• Taxi Drivers: Lower Death Rates from Alzheimer's
• Prehistoric Rock and Ocean Anoxic Event
• Physicists 'Bootstrap' Validity of String Theory
• Binary Star Found Near Milky Way's Black Hole
• New Neurons That Suppress Food Intake
• Exoplanet Trappist-1 B: Atmosphere?
• Naughty or Nice? Many Parents Rely On Threats
• Violence of the Early Bronze Age
• Anglerfish's Fishing Rod: Unique Motor Control

Trending Topics

Strange & offbeat.